Evaluation of the hemostatic state, carbohydrate and lipid metabolism in young women with abdominal obesity and hypertension

Aim of this study was to determine the characteristics of the laboratory parameters of hemostasis, carbohydrate and lipid metabolism in women with metabolic syndrome, isolated abdominal obesity or with hypertension.

Materials and methods. The study included 71 women aged 30 – 44 years and was conducted at laboratory study of hemostasis system, carbohydrate and lipid metabolism.

Results. In women with abdominal obesity and arterial hypertension we found an increased levels of glucose, total cholesterol, LDL-C and triglycerides and a decrease in a concentration of HDL-C compared to healthy women. The study of hemostasis revealed prothrombotic changes in the form of activation of coagulation hemostasis and fibrinolysis system activity.

Conclusions. The disorders of carbohydrate and lipid metabolism are very prevalent in young women with abdominal obesity and hypertension with every second woman meeting the criteria for the metabolic syndrome. The most pronounced signs of activation of blood coagulation markes was seen in women with abdominal obesity and hypertension. In women with the individual components of the metabolic syndrome there were no significant changes in carbohydrate and lipid metabolism, although we saw an early signs of activation of hemocoagulation.

1. Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. AJP: Gastrointestinal and Liver Physiology. 2011;300(5):G697-G702. doi: 10.1152/ajpgi.00426.2010

2. Мычка В. Б., Чазова И. Е. Метаболический синдром: миф или реальность? // Системные гипертензии. – 2008. – Т. 2. – С. 50-53. [Mychka VB, Chazova IE Metabolic syndrome. Sistemnye Gipertenzii. 2009;1:50-53. (In Russ)]

3. Devaraj S, Jialal I. Dysfunctional Endothelial Progenitor Cells in Metabolic Syndrome. Experimental Diabetes Research. 2012;2012:1-5. doi: 10.1155/2012/585018

4. Liu G. The association between metabolic syndrome and vascular endothelial dysfunction in adolescents. Experimental and Therapeutic Medicine. 2013. doi: 10.3892/etm.2013.1055

5. Pérez MP, Moore-Carrasco R, González RD, Fuentes QE, Palomo GI. Gene expression of adipose tissue, endothelial cells and platelets in subjects with metabolic syndrome (Review). Molecular Medicine Reports. 2012. doi: 10.3892/mmr.2012.785

6. Шишова А. С., Горяйнов И. И., Лукашов А. А. Влияние терапии на показатели активности иммунного воспаления, нарушений упруго-эластических свойств сосудистого русла у больныхартериальной гипертензией с метаболическим синдромом // Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармация. – 2012. – Т. 18. – №. 10-1 (129). [Shishova AS, Gorjajnov II, Lukashov AA. The influence of the therapy on indicens of immune inflammation, abnormalities of bloodstream elastans at hypertensive patients with a metabolic syndrome. Nauchnye Vedomosti Belgorodskogo Gosudarstvennogo Universiteta. Seria: Meditsina. Farmatsia. 2012;18(129):Vypusk 18/1. (In Russ)]

7. Чулков Вл.С., Сумеркина В.А., Абрамовских О.С., Чулков В.С. Чулков В.С. Частота неалкогольной жировой болезни печени у молодых пациентов с абдоминальным ожирением на фоне артериальной гипертензии/Вл. С. Чулков, ВА Сумеркина, ОС Абрамовских, ВС Чулков // Экспериментальная и клиническая гастроэнтерология. – 2014. – T. 111. – №11– С. 42-45. [Chulkov VlS, Sumerkina VA, Abramovskikh OS, Chulkov VS Frequency of non-alcoholic fatty liver disease in young patients with abdominal obesity on the background of hypertension. Eksperimental'naya I Klinicheskaya Gastroenterologiya. 2014;111(11):42-45. (In Russ)]

8. Boden-Albala B, Sacco RL, Lee HS, Grahame-Clarke C, Rundek T, Elkind MV, et al. Metabolic Syndrome and Ischemic Stroke Risk: Northern Manhattan Study. Stroke. 2007;39(1):30-5. doi: 10.1161/strokeaha.107.496588

9. Чернавский С.В., Фурсов А.Н., Потехин Н.П., Яковлев В.Н. Обоснование мероприятий по профилактике кардиоцеребральных осложнений при метаболическом синдроме на основе методов математического прогнозирования // Клиницист. – 2011. – №. 4. – С. 21-26. [Chernavskii SV, Fursov AN, Potekhin NP, Yakovlev VN. Rationale for prevention of cardiocerebral complications in the metabolic syndrome based on mathematical forecasting techniques. Klinitsist. 2011;(4):21-25. (In Russ)]

10. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. American Journal of Physiology-Endocrinology And Metabolism. 2001;280(5):E745-E51

11. Meas T, Deghmoun S, Chevenne D, Gaborit B, Alessi MC, LÉVy-Marchal C. Plasminogen activator inhibitor type-1 is an independent marker of metabolic disorders in young adults born small for gestational age. Journal of Thrombosis and Haemostasis. 2010;8(12):2608-13. doi: 10.1111/j.1538-7836.2010.04037.x

12. Palomo I, Alarcón M, Moore-Carrasco R, Argilés J. Hemostasis alterations in metabolic syndrome (Review). International Journal of Molecular Medicine. 2006. doi: 10.3892/ijmm.18.5.969

13. Lee DE, Kehlenbrink S, Lee H, Hawkins M, Yudkin JS. Getting the message across: mechanisms of physiological cross talk by adipose tissue. AJP: Endocrinology and Metabolism. 2009;296(6):E1210-E29. doi: 10.1152/ajpendo.00015.2009

14. Плохая А. А. Современные аспекты лечения метаболического синдрома // Ожирение и метаболизм. – 2011. – №. 3. – С. 31-37. [Plokhaya AA. Sovremennye aspekty lecheniya metabolicheskogosindroma.Obesity and metabolism. 2011;8(3):31-37. (In Russ)] doi: 10.14341/2071-8713-4834

15. Challa TD, Beaton N, Arnold M, Rudofsky G, Langhans W, Wolfrum C. Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling. Journal of Biological Chemistry. 2011;287(9):6421-30. doi: 10.1074/jbc.M111.310342

16. Papageorgiou N, Tousoulis D, Androulakis E, Giotakis A, Siasos G, Latsios G, et al. Lifestyle Factors and Endothelial Function. Current Vascular Pharmacology. 2012;10(1):94-106. doi: 10.2174/157016112798829788

17. De La Fuente M, M. De Castro N. Obesity as a Model of Premature Immunosenescence. Current Immunology Reviews. 2012;8(1):63-75. doi: 10.2174/157339512798991290

18. Lafontan M. Historical perspectives in fat cell biology: the fat cell as a model for the investigation of hormonal and metabolic pathways. AJP: Cell Physiology. 2011;302(2):C327-C59. doi: 10.1152/ajpcell.00168.2011

19. Srinivasan V, Ohta Y, Espino J, A. Pariente J, B. Rodriguez A, Mohamed M, et al. Metabolic Syndrome, its Pathophysiology and the Role of Melatonin. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery. 2013;7(1):11-25. doi: 10.2174/187221413804660953

20. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obesity Reviews. 2010;11(1):11-8. doi: 10.1111/j.1467-789X.2009.00623.x